Download PDF
Pharmacopsychiatry 2020; 53(02): 65-70
DOI: 10.1055/a-1021-8827
Original Paper
© Georg Thieme Verlag KG Stuttgart · New York

The Effects of Co-prescription of Pantoprazole on the Clozapine Metabolism

Maxim Kuzin‡
1   Psychiatric and Psychotherapeutic Private Clinic Clienia Schlössli, Academic Teaching Hospital of the University of Zurich, Oetwil am See, Switzerland
,
Georgios Schoretsanitis  ‡
2   The Zucker Hillside Hospital, Psychiatry Research, Northwell Health, Glen Oaks, New York, USA
,
Ekkehard Haen
3   Department of Psychiatry and Psychotherapy, Clinical Pharmacology, University of Regensburg, Regensburg, Germany
4   Department of Pharmacology and Toxicology, University of Regensburg, Regensburg, Germany
,
Gerhard Dammann
5   Psychiatric Services of Thurgovia, Academic Teaching Hospital of the Medical University of Salzburg, Münsterlingen, Switzerland
,
Christoph Hiemke
6   Department of Psychiatry and Psychotherapy and Institute of Clinical Chemistry and Laboratory Medicine, University Medical Center of Mainz, Germany
,
Gerhard Gründer
7   Department of Molecular Neuroimaging, Central Institute of Mental Health, Medical Faculty Mannheim, University of Heidelberg, Mannheim, Germany
,
Michael Paulzen
8   Alexianer Hospital Aachen, Aachen, Germany
9   Department of Psychiatry, Psychotherapy and Psychosomatics, RWTH Aachen University, Aachen, Germany, and JARA – Translational Brain Medicine, Jülich, Germany
› Author Affiliations
Further Information

Publication History

received 20 June 2019
revised 29 August 2019

accepted 20 September 2019

Publication Date:
15 October 2019 (online)

Also available at
    Permissions and Reprints

Abstract

Background Polypharmacy including somatic medications such as proton pump inhibitors is a common phenomenon in psychiatric care. The aim of this study was to evaluate the pantoprazole effects on clozapine metabolism.

Methods A large therapeutic drug-monitoring database containing plasma concentrations of CLZ was analyzed. The results were stratified into four groups: a non-smoking (n=250) and a smoking group (n=326), and two groups co-medicated with pantoprazole: non-smokers (n=26) and smokers (n=29). The analysis was based on the non-parametrical Mann-Whitney U test (M-W-U) with a significance level of 0.05.

Results Differences reached statistical significance for pharmacokinetic parameters between CLZ monotherapy and co-medication with pantoprazole neither in smokers nor in non-smokers (p>0.05 for M-W-U in pairwise comparisons). In patients with clozapine monotherapy, smokers had a higher daily dosage of CLZ compared to non-smokers (mean dosage 363±181 vs. 291±145 mg/day, p<0.001 for M-W-U).

Conclusions Adding pantoprazole to an ongoing treatment with clozapine does not alter the metabolism of clozapine to a significant extent.

Key words

therapeutic drug monitoring - clozapine - pantoprazole - CYP2C19 - smokers
 

  • References

  • 1 Siskind D, Siskind V, Kisely S. Clozapine response rates among people with treatment-resistant schizophrenia: Data from a systematic review and meta-analysis. Can J Psychiatry 2017; 62: 772-777
    CrossrefPubMedGoogle Scholar
  • 2 Frank J, Lang M, Witt SH. et al. Identification of increased genetic risk scores for schizophrenia in treatment-resistant patients. Mol Psychiatry 2015; 20: 150-151
    PubMedGoogle Scholar
  • 3 Toth K, Csukly G, Sirok D. et al. Potential role of patients' CYP3A-status in clozapine pharmacokinetics. Int J Neuropsychopharmacol 2017; 20: 529-537
    CrossrefPubMedGoogle Scholar
  • 4 Hiemke C, Bergemann N, Clement HW. et al. Consensus guidelines for therapeutic drug monitoring in neuropsychopharmacology: Update 2017. Pharmacopsychiatry 2018; 51: 9-62
    Article in Thieme ConnectPubMedGoogle Scholar
  • 5 Bondolfi G, Morel F, Crettol S. et al. Increased clozapine plasma concentrations and side effects induced by smoking cessation in 2 CYP1A2 genotyped patients. Ther Drug Monit 2005; 27: 539-543
    CrossrefPubMedGoogle Scholar
  • 6 Gee SH, Taylor DM, Shergill SS. et al. Effects of a smoking ban on clozapine plasma concentrations in a nonsecure psychiatric unit. Ther Adv Psychopharmacol 2017; 7: 79-83
    CrossrefPubMedGoogle Scholar
  • 7 Augustin M, Schoretsanitis G, Pfeifer P. et al. Effect of fluvoxamine augmentation and smoking on clozapine serum concentrations. Schizophrenia research 2019; 210: 143-148
    CrossrefPubMedGoogle Scholar
  • 8 Guthrie B, Makubate B, Hernandez-Santiago V. et al. The rising tide of polypharmacy and drug-drug interactions: population database analysis 1995-2010. BMC Med 2015; 13: 74
    CrossrefPubMedGoogle Scholar
  • 9 Patterson SM, Cadogan CA, Kerse N. et al. Interventions to improve the appropriate use of polypharmacy for older people. Cochrane Database Syst Rev 2014; DOI: 10.1002/14651858.CD008165.pub3.
    PubMedGoogle Scholar
  • 10 Gee S, Dixon T, Docherty M. et al. Optimising plasma levels of clozapine during metabolic interactions: a review and case report with adjunct rifampicin treatment. BMC Psychiatry 2015; 15: 195
    CrossrefPubMedGoogle Scholar
  • 11 Hommers L, Scharl M, Hefner G. et al. Comedication of valproic acid is associated with increased metabolism of clozapine. J Clin Psychopharmacol 2018; 38: 188-192
    CrossrefPubMedGoogle Scholar
  • 12 Spina E, Hiemke C, de Leon J. Assessing drug-drug interactions through therapeutic drug monitoring when administering oral second-generation antipsychotics. Expert opinion on drug metabolism & toxicology 2016; 12: 407-422
    CrossrefPubMedGoogle Scholar
  • 13 Li W, Zeng S, Yu LS. et al. Pharmacokinetic drug interaction profile of omeprazole with adverse consequences and clinical risk management. Ther Clin Risk Manag 2013; 9: 259-271
    PubMedGoogle Scholar
  • 14 Kantor ED, Rehm CD, Haas JS. et al. Trends in prescription drug use among adults in the United States from 1999–2012. JAMA 2015; 314: 1818 – 1831;
    PubMedGoogle Scholar
  • 15 Schoretsanitis G, Stegmann B, Hiemke C. et al. Pharmacokinetic patterns of risperidone-associated adverse drug reactions. Eur J Clin Pharmacol 2016; 72: 1091-1098
    CrossrefPubMedGoogle Scholar
  • 16 Wedemeyer RS, Blume H. Pharmacokinetic drug interaction profiles of proton pump inhibitors: An update. Drug safety 2014; 37: 201-211
    CrossrefPubMedGoogle Scholar
  • 17 Olesen OV, Linnet K. Contributions of five human cytochrome P450 isoforms to the N-demethylation of clozapine in vitro at low and high concentrations. J Clin Pharmacol 2001; 41: 823-832
    CrossrefPubMedGoogle Scholar
  • 18 Molins C, Carceller-Sindreu M, Navarro H. et al. Plasma ratio of clozapine to N-desmethylclozapine can predict cognitive performance in treatment-resistant psychotic patients. Psychiatry Res 2017; 258: 153-157
    CrossrefPubMedGoogle Scholar
  • 19 Rajji TK, Mulsant BH, Davies S. et al. Prediction of working memory performance in schizophrenia by plasma ratio of clozapine to N-desmethylclozapine. Am J Psychiatry 2015; 172: 579-585
    CrossrefPubMedGoogle Scholar
  • 20 Castberg I, Westin AA, Skogvoll E. et al. Effects of age and gender on the serum levels of clozapine, olanzapine, risperidone, and quetiapine. Acta Psychiatr Scand 2017; 136: 455-464
    CrossrefPubMedGoogle Scholar
  • 21 Kuzin M, Schoretsanitis G, Haen E. et al. Effects of the proton pump inhibitors omeprazole and pantoprazole on the cytochrome P450-mediated metabolism of venlafaxine. Clin Pharmacokinet 2017; DOI: 10.1007/s40262-017-0591-8.
    CrossrefPubMedGoogle Scholar
  • 22 Mookhoek EJ, Loonen AJM. Does the change of omeprazole to pantoprazole affect clozapine plasma concentrations?. Br J Clin Pharmacol 2002; 53: 545
    PubMedGoogle Scholar
  • 23 Bader W, Melchner D, Nonenmacher T. et al. Determination of five commonly used antipsychotics in human serum by high performance-liquid chromatography (HPLC) and electrochemical detection. Pharmacopsychiatry 2005; 38: 4
    Article in Thieme ConnectPubMedGoogle Scholar
  • 24 Bader W. Therapeutisches Drug Monitoring bei Antipsychotika: die Entwicklung der Analytik von Antipsychotika und ihre Relevanz bei der Therapieleitung schizophrener Patienten am Beispiel des Arzneistoffes Risperidon. Pentling: Saska; 2009
    Google Scholar
  • 25 Paul L, Musshoff F, Aebi B. et al. Richtlinie der GTFCh zur Qualitätssicherung bei forensisch-toxikologischen Untersuchungen. Toxichem Krimtech 2009; 76: 142-176
    PubMedGoogle Scholar
  • 26 US Food & Drug Administration Guidance for Industry on Biomedical Method Validation 2001
    PubMed
  • 27 ICH International Conference on Harmonisation Harmonised Tripartite Guideline, Validation of Analytical Procedures: Test and Methodology. International conference on harmonisation of technical requirements for registration of pharmaceuticals for human use 1996
    PubMed
  • 28 Andersson T, Regardh CG, Dahl-Puustinen ML. et al. Slow omeprazole metabolizers are also poor S-mephenytoin hydroxylators. Ther Drug Monit 1990; 12: 415-416
    CrossrefPubMedGoogle Scholar
  • 29 Zanger UM, Turpeinen M, Klein K. et al. Functional pharmacogenetics/genomics of human cytochromes P450 involved in drug biotransformation. Anal Bioanal Chem 2008; 392: 1093-1108
    CrossrefPubMedGoogle Scholar
  • 30 Ishizaki T, Horai Y. Review article: cytochrome P450 and the metabolism of proton pump inhibitors–emphasis on rabeprazole. Aliment Pharmacol Ther 1999; 13 (S3) 27-36
    PubMedGoogle Scholar
  • 31 Ogilvie BW, Yerino P, Kazmi F. et al. The proton pump inhibitor, omeprazole, but not lansoprazole or pantoprazole, is a metabolism-dependent inhibitor of CYP2C19: implications for coadministration with clopidogrel. Drug Metab Dispos 2011; 39: 2020-2033
    CrossrefPubMedGoogle Scholar
  • 32 Yu KS, Yim DS, Cho JY. et al. Effect of omeprazole on the pharmacokinetics of moclobemide according to the genetic polymorphism of CYP2C19. Clin Pharmacol Ther 2001; 69: 266-273
    PubMedGoogle Scholar
  • 33 Furuta T, Sugimoto M, Kodaira C. et al. Influence of low-dose proton pump inhibitors administered concomitantly or separately on the anti-platelet function of clopidogrel. J Thromb Thrombolysis 2017; 43: 333-342
    CrossrefPubMedGoogle Scholar
  • 34 Masubuchi N, Li AP, Okazaki O. An evaluation of the cytochrome P450 induction potential of pantoprazole in primary human hepatocytes. Chem Biol Interact 1998; 114: 1-13
    CrossrefPubMedGoogle Scholar
  • 35 Diaz FJ, Eap CB, Ansermot N. et al. Can valproic acid be an inducer of clozapine metabolism?. Pharmacopsychiatry 2014; 47: 89-96
    Article in Thieme ConnectPubMedGoogle Scholar
  • 36 van der Weide J, Steijns LS, van Weelden MJ. The effect of smoking and cytochrome P450 CYP1A2 genetic polymorphism on clozapine clearance and dose requirement. Pharmacogenetics 2003; 13: 169-172
    CrossrefPubMedGoogle Scholar
  • 37 Bozikas VP, Papakosta M, Niopas I. et al. Smoking impact on CYP1A2 activity in a group of patients with schizophrenia. Eur Neuropsychopharmacol 2004; 14: 39-44
    CrossrefPubMedGoogle Scholar
  • 38 Rostami-Hodjegan A, Amin AM, Spencer EP. et al. Influence of dose, cigarette smoking, age, sex, and metabolic activity on plasma clozapine concentrations: A predictive model and nomograms to aid clozapine dose adjustment and to assess compliance in individual patients. J Clin Psychopharmacol 2004; 24: 70-78
    CrossrefPubMedGoogle Scholar
  • 39 Schoretsanitis G, Kane JM, Ruan CJ. et al. A comprehensive review of the clinical utility of and a combined analysis of the clozapine/norclozapine ratio in therapeutic drug monitoring for adult patients. Exp Rev Clin Pharmacol 2019; 12: 603-621
    CrossrefPubMedGoogle Scholar